Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.
Pharmacy benefit managers are increasingly measuring a patient's outcome in the context of adherence.
Second to market and dismissed as inferior to the competition, Sanofi's Aubagio seemed destined for lower-tier status. Here's how it overcame the initial obstacles and, five years later, become a potent market force
Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?
The drugmaker eliminated its U.S. primary care, disease-focused endocrinology, and hospital chronic-care sales teams.
Two point-of-care companies have received hundreds of millions of dollars in funding. One of them, Outcome Health, is facing allegations about padding data.
Still, most experts characterize this year's newly approved women's health drugs as modest improvements rather than groundbreaking advances in medicine.
Amgen's Prolia tops the list, according to data compiled by EvaluatePharma.
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.
Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?
Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.
Two recent cash infusions suggest investors are bullish on point-of-care advertising. Is the channel ready for its moment in the spotlight?
Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.
What's holding back value-based pricing deals from moving beyond the pilot phase?
The goal is to further cement point of care as a mainstream media channel.
Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.
A particular focus is put on the emerging research about cannabis and its benefits for the human body.
It's the third year of consecutive growth for spending on accredited CME, according to the Accreditation Council for Continuing Medical Education.
Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.
The deal highlights ongoing interest in the influential point-of-care market.
Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
The chip-in-a-pill combines antipsychotic Abilify with an ingestible sensor made by Proteus.
Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.
Pfizer to provide Ibrance for free during NICE analysis; the FDA approves new ALS drug; people turn to Twitter to tell stories about pre-existing conditions
Execs stressed the importance of collaboration, consumer-mindedness.
Researchers still don't know why Americans who are prescribed a prescription drug to treat a chronic condition or disease so often fail to fill those prescriptions.
Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.
AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.
The research found a reduction in utilization of medications used to treat depression, nausea, and psychosis when looking at data for Medicaid beneficiaries.
How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?
A tool kit of pharma case studies and advice for healthcare brands in making behavioral science a foundational part of a marketing strategy.
The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.
While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.
Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs
There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.
Pharmaceutical companies often blur the lines between a drug's risks and benefits in ads, and that frustrates physicians.
Pfizer and Bristol-Myers Squibb were the top spenders last year.
The data stems from the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.
He describes his current charge as "transforming a more creative occupation into a science."
Valeant added 250 primary care sales reps to promote its Salix portfolio.
J&J discloses list prices for its drugs; Kite's CAR-T therapy meets study goals; healthcare providers seek to engage patients in decisionmaking
Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.
When discussing the nation's ability to stomach orphan drug costs, an analyst has called the price tag "the straw that breaks the camel's back."
Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.
Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.
Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.
If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.
The drugmaker is planning a commercial boost for its HIV-prevention drug.
Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.
Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.
WPP will create "Team WBA," a bespoke team that would work on traditional and digital advertising, media, and PR.
Merck details price increases for its drugs; Trump's call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit
But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?
A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.
A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.
Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.
That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"
"In Australia, we are the healthcare industry," he says.
The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.
The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?
Find out what stories generated the most interest among our readers.
Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine
Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.
Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.
Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey
The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.
More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.
Specialty pharma ace Umer Raffat, a senior analyst at Evercore ISI, shares his 2016 postmortem and a few quick-hit predictions for 2017.
"This is not your grandfather's launch," said Shawn Tomasello, chief commercial officer of Kite Pharma.
How pharma distributes information to doctors is changing as rapidly as how doctors prefer to receive and process such information
BMS and Pfizer outspent Johnson & Johnson two-to-one in advertising for their oral anticoagulant last year.
Tech companies and Bernie Sanders have found the millennial audience easy to crack. Organizations in and around healthcare? Not so much.
MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.
Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.
Merck doled out more than $2 million to target doctors in the first half of the year, while BMS spent only $863,000.
The firm will handle communications for scar treatment Mederma and is already managing the product launch of cellulite-treatment product Cellfina, the 10-year anniversary of injectable Radiesse, and introducing a product line.
73% of derms take industry money; Area 23, Klick Health, and UnitedHealthcare win big at the MM&M Awards; IPG launches healthcare media agency
The FDA to require black-box warnings for hep.-C drugs; AstraZeneca's Brilinta fails to meet study goals; ICER says PD-1s are too pricey
The inside story on a campaign for the ages, as told by the individuals who worked on it.
For some people in the industry ecosystem, the appeal of promo knickknacks endures.
And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.
Patient advocacy groups stay silent in drug-pricing debate; Opdivo to be tested in combination with Nektar drug; 25% of FDA employees now work for industry
The organizations are using innovation competitions to challenge internal and external audiences with coming up with new ideas.
Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.
Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight
Sales reps are now more likely to engage with physicians through nonpersonal promotion than in-person visits with doctors at their offices, a ZS report finds.
Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?
One analyst envisions how a first-line approval could set up Keytruda for success in other settings.
CEO Brent Saunders also said the drugmaker will not increase the price of drugs nearing patent expiration.
In 2011 the drugmaker spent $9.4 million on branded ads for the EpiPen. By 2015, branded ad spending hit $43 million.
The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.
Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.
Will this payer pressure pose an existential threat to co-pay cards even though patients love them?
Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?
Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.
The current reimbursement climate is more likely to impact how drugmakers order their global product launches than the U.K.'s vote to exit the E.U.
Only one new osteoporosis drug has been approved over the last six years.